米泔水制白术增强溃疡性结肠炎疗效的LCN2焦亡机制
该研究以DSS诱导的小鼠溃疡性结肠炎模型比较米泔水制白术(R-AMR)与生白术的疗效,发现两者均能降低DAI和组织病理评分、调节炎症因子并修复肠屏障,R-AMR更优。网络分析与实验验证提示白术内酯I通过靶向抑制LCN2,减少NLRP3/Caspase 1/GSDMD焦亡通路活化,从而保护肠黏膜屏障。
要点
- 米泔水制白术较生白术对UC小鼠疗效更优,可降低DAI与病理评分。
- 白术内酯I靶向抑制LCN2,减轻NLRP3/Caspase 1/GSDMD焦亡。
- 白术类药材治疗UC的机制与修复肠上皮黏膜屏障相关。
核心结论
- 生白术与米泔水制白术均对UC小鼠有保护作用,米泔水制白术疗效更优。
- 白术内酯I通过靶向抑制LCN2减轻细胞焦亡,保护肠上皮黏膜屏障。
研究设计与样本
- 建立DSS诱导的小鼠UC模型,比较米泔水制白术与生白术的体内疗效。
- 采用生物信息学、机器学习和分子对接识别核心靶点并探索机制。
- 以LPS诱导NCM460细胞建立UC细胞模型,并进行LCN2 siRNA转染实验。
- 通过免疫荧光、WB和RT-qPCR进行体外验证,并用体内实验验证通路作用。
主要发现
- 米泔水制白术与生白术均降低UC小鼠DAI评分和组织病理学评分。
- 两者均下调促炎因子、上调抗炎因子,并增加ZO-1、Claudin-1表达以修复肠上皮黏膜屏障。
- 生物信息学与机器学习提示LCN2和TIMP1为UC关键靶点,NOD样受体信号通路为代表性通路之一。
- 分子对接显示白术内酯I与LCN2有较强亲和力,为增强米泔水制白术疗效的活性成分之一。
- 靶向抑制LCN2可减少NLRP3炎症小体、Caspase 1活化及GSDMD-N表达,降低IL-1β、IL-18、TNF-α、IL-6释放。
临床怎么用
- 对UC患者可考虑在辨证基础上使用白术,米泔水制或可增强疗效。
- 白术内酯I及LCN2/NLRP3/Caspase 1/GSDMD轴可作为UC中药干预的潜在靶点。
局限性
- 研究仅为动物与细胞实验,尚缺乏临床人群验证。
- 米泔水制白术的疗效优势及机制仍需更多实验与临床研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Atractylodes Macrocephala Rhizome (AMR), the dried rhizome of Atractylodes macrocephala Koidz (family Asteraceae), is a commonly used Chinese herbal medicine for treating ulcerative colitis (UC) and has extensive applications in both Traditional Chinese Medicine (TCM) and modern medicine. The therapeutic effects of its distinctive processed variety, rice-washed water processed Atractylodis Macrocephalae Rhizoma (Migan Shui Piao Baizhu, R-AMR), have yet to be reported, and its potential mechanisms of action require further exploration. AIM OF THE STUDY: This study aims to compare the therapeutic effects of R-AMR and raw AMR on UC mice and further explore their mechanisms of action, thereby providing insights into the processing mechanism of AMR using rice-washed water. METHODS: Firstly, a DSS-induced mouse UC model was established in vivo. The efficacy of treatment with rice-washed water processed AMR in improving UC was evaluated by DAI scores, histopathological changes, serum inflammatory cytokines, tight junction proteins (ZO-1, Claudin-1), and mucin (MUC2) levels. Then, bioinformatics, machine learning, and molecular docking were integrated to identify core disease targets and explore the mechanism of R-AMR in treating UC. Nextly, an LPS-induced UC cell model was established using NCM460 cells, and LCN2 siRNA-transfected cell experiments were conducted. The biological effects and mechanisms of action of key targets were validated in vitro through immunofluorescence, WB, and RT-qPCR techniques. Finally, we validated the roles of the above-identified pathways in the treatment of UC with AMR through in vivo experiments. RESULTS: In in vivo efficacy experiments, both R-AMR and raw AMR effectively reduced DAI scores and histopathological scores in UC mice. They downregulated proinflammatory factors and upregulated anti-inflammatory factors while increasing tight junction protein expression (ZO-1, Claudin-1) to restore damaged intestinal epithelial mucosal barriers. R-AMR demonstrated superior therapeutic effects compared to raw AMR. Bioinformatics and machine learning results indicate that Lipocalin 2 (LCN2) and Tissue inhibitor of metalloproteinase 1 (TIMP1) is a key target in UC, with the NOD-like receptor signaling pathway being one of its representative pathways. Molecular docking results reveal that Atractylenolide I (Atr I) has a strong affinity for LCN2 and is one of the active components enhancing the efficacy of R-AMR. In vitro experiments demonstrate that Atr I restores tight junctions between LPS-induced NCM460 cells. Targeted inhibition of LCN2 reduces NLRP3 inflammasome, Caspase 1 activation, and GSDMD-N expression, decreases proinflammatory factor release (IL-1β, IL-18, TNF-α, IL-6), and alleviates UC inflammatory responses. In vivo experiments verified that the therapeutic effect of AMR on UC is associated with the LCN2/NLRP3/Caspase 1/GSDMD pyroptosis pathway. CONCLUSIONS: Both raw AMR and R-AMR exhibit protective effects against UC, with R-AMR displaying superior therapeutic outcomes. Its bioactive constituent Atr I attenuates pyroptosis through targeted inhibition of LCN2, leading to preservation of the intestinal epithelial mucosal barrier and subsequent amelioration of UC symptoms.
引用
- Zhang A, Wen R, Zheng H, et al. Enhancing the efficacy of ulcerative colitis treatment by inhibiting LCN2-mediated pyroptosis through traditional processing techniques: With the rhizome of Atractylodes macrocephala Koidz. as an example. J Ethnopharmacol. 2026. PMID: 42302942. doi:10.1016/j.jep.2026.122037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。